EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Imaging of ROR1 expression in tumors using radiolabeled affibody molecules

Cornelia Westerberg, Tianqi Xu, Maria Marth, Moeen Ud-Din, Russol Abushaia, Tilde Hagelin, Stefan Ståhl, Anna Orlova, Vladimir Tolmachev, John Löfblom, Anzhelika Vorobyeva

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8104-8115

DOI: 10.1007/s00259-026-08106-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 01.08.2026. Verfasst von Cornelia Westerberg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, 100 44, Stoc…. Hauptthemen laut MEDLINE: Receptor Tyrosine Kinase-like Orphan Receptors, Recombinant Fusion Proteins, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uppsala University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an attractive molecular target for anti-tumor therapies undergoing late-stage clinical development. Quantitative imaging of ROR1 expression could enable identification of patients likely to respond to such treatments. This study aimed to assess the feasibility of specific in vivo imaging of ROR1 using radiolabeled affibody molecules.

Methods

The affibody molecule ZROR1:A10, with high affinity for human (4 nM) and murine (2 nM) ROR1, was labeled with indium-111 using a DOTA chelator. In vitro binding specificity, affinity, and cellular processing were evaluated using a panel of ROR1-expressing cell lines. The affibody [ 111 In]In-DOTA-Zcov19s, which does not bind ROR1, served as a nonspecific control. The biodistribution of [ 111 In]In-DOTA-ZROR1:A10 and [ 111 In]In-DOTA-Zcov19s was measured in immunodeficient mice bearing ROR1-positive tumors, with ROR1-negative Ramos xenografts used as an additional specificity control. Results [ 111 In]In-DOTA-ZROR1:A10 bound specifically to ROR1-expressing cells, with significantly higher uptake than [ 111 In]In-DOTA-Zcov19s. The apparent equilibrium dissociation constant for ROR1 binding in vitro was 1–4 nM. Tumor uptake of [ 111 In]In-DOTA-ZROR1:A10 in MDA-MB-468 xenografts was saturable and significantly (p < 0.05) higher than in Ramos tumors, as well as higher than uptake of the control affibody. At 4 h post‑injection of 1 µg (50 µg/kg), tumor‑to‑blood, tumor‑to‑bone, and tumor‑to‑muscle ratios were 14 ± 6, 19 ± 6, and 11 ± 1, respectively. Micro-SPECT/CT imaging clearly visualized ROR1‑positive tumors and discriminated them from ROR1‑negative xenografts.

Conclusion

The preclinical evaluation shows that visualization of ROR1-expressing tumors using a radiolabeled affibody molecule is feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor Tyrosine Kinase-like Orphan ReceptorsRecombinant Fusion ProteinsGene Expression Regulation, NeoplasticAnimalsHumansMiceCell Line, TumorIndium RadioisotopesTissue DistributionFemaleIsotope Labeling

Stichwörter der Autor:innen

AffibodyMDA-MB-468ROR1Radionuclide imaging

Substanzen

Receptor Tyrosine Kinase-like Orphan ReceptorsIndium RadioisotopesROR1 protein, humanRecombinant Fusion ProteinsRor1 protein, mouseIndium-111

Autor:innen und Institutionen

  • Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, 100 44, Stockholm, Sweden.
  • Department of Immunology, Genetics and Pathology, Uppsala University, 751 85, Uppsala, Sweden.
  • Department of Medicinal Chemistry, Uppsala University, 751 23, Uppsala, Sweden.
  • Department of Immunology, Genetics and Pathology, Uppsala University, 751 85, Uppsala, Sweden. anzhelika.vorobyeva@igp.uu.se.

Förderung

  • Uppsala University

Zitieren

APA

Westerberg, C., Xu, T., Marth, M., Ud-Din, M., Abushaia, R., Hagelin, T., Ståhl, S., Orlova, A., Tolmachev, V., Löfblom, J., & Vorobyeva, A. (2026). Imaging of ROR1 expression in tumors using radiolabeled affibody molecules. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8104-8115. https://doi.org/10.1007/s00259-026-08106-8

Vancouver

Westerberg C, Xu T, Marth M, Ud-Din M, Abushaia R, Hagelin T, et al. Imaging of ROR1 expression in tumors using radiolabeled affibody molecules. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8104-8115. doi:10.1007/s00259-026-08106-8

BibTeX
@article{Westerberg2026,
  author = {Westerberg, Cornelia and Xu, Tianqi and Marth, Maria and Ud-Din, Moeen and Abushaia, Russol and Hagelin, Tilde and Ståhl, Stefan and Orlova, Anna and Tolmachev, Vladimir and Löfblom, John and Vorobyeva, Anzhelika},
  title = {Imaging of ROR1 expression in tumors using radiolabeled affibody molecules},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8104--8115},
  doi = {10.1007/s00259-026-08106-8}
}
Kostenlos starten →